- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02865941
Target Fortification of Breast Milk: How Often Breast Milk Needs to be Measured? (TFO2)
Target Fortification of Breast Milk: The Effect of Different Schedules for Milk Analysis on the Growth and Development of Preterm Infants.
It has been observed that target fortification on different schedules leads to meal to meal variation. It changes the ratio of protein to energy and the percentage of carbohydrate to non-protein energy which may, affect growth. In the past, the investigators have analyzed the outcomes of breast milk composition when target fortification is done with different analysis schedules. The investigators were able to measure the macronutrient intake for different milk analysis schedules via a theoretical model and show that the more frequent schedules reduce the variation of fortified-breast milk, whereas a reduced schedule leads to a high variation of macronutrients. It was observed that, in all the breast milk samples measured twice per week, infants achieved on average the recommended macronutrients in line with current recommendations. Nonetheless, the model only looks at the macronutrient intake and does not investigates the relationship between macronutrient variation and its effect on growth.
The aim of the current study is to compare a frequent schedule of measurement of macronutrient analysis with a reduced schedule of measurement and to study its affect on growth, protein accretion and metabolic parameter.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8S 4K1
- Faculty of Health Science, McMaster Children's Hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Gestational age < 30 weeks (maternal dates or early fetal ultrasound);
- Tolerating an enteral intake of ≥100 mL/kg/d for ≥ 24h;
- Subject is anticipated to receive the intervention for ≥ 3 consecutive weeks after full enteral feeding (≥150 mL/kg/d) has been achieved;
- Written informed consent has been obtained from the infant's legal representative.
- Multiple births: Each infant will be included in the study if he/she meets the study criteria, and siblings will be individually randomized to one or other of the treatment arms.
- Discussion with Most Responsible Physician (MRP) and the staff in order to discuss any potential transfer during the next 7 days.
Exclusion Criteria:
- Gastrointestinal malformation, major congenital anomalies and chromosomal abnormalities;
- Babies with enterostoma or short gut syndrome;
- Infants fed more than 25% of mean caloric intake for a consecutive week with formula milk;
- Fluid restriction <140 mL/kg/d for ≥ 3 consecutive days;
- Sepsis - all infants with gram-negative sepsis will be removed from the study;
- Necrotizing enterocolitis, defined by feeding intolerance associated with positive x-ray findings (pneumatosis intestinalis - Bell Stage 2; air in the biliary tract or free air in the peritoneum - Bell Stage 3);
- Renal disease, defined by symptoms (oliguria, anuria, proteinuria, hematuria) associated with an increased blood urea nitrogen >10 mmol/L and creatinine of 130mmol/L
- Participation in another clinical trial that may provide an alternative nutritional intervention, which might affect the outcomes of this study. outcomes of this study;
- Probability of transfer to another neonatal intensive care unit or level II nursery outside the McMaster Children's Hospital, as discussed with the most responsible physician (MRP)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: 5 milk analysis
|
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.
|
|
Experimental: 1 milk analysis
|
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.
Modular product supplementation is based on most recent breast analysis done for the participant.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Growth during first three weeks of intervention
Zeitfenster: first three weeks during intervention before 36 weeks of gestation
|
first three weeks during intervention before 36 weeks of gestation
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Daily Nutrient intake (kcal, lactose, protein, fat) measured with conventional milk analysis
Zeitfenster: from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation
|
from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation
|
|
|
Weight Gain
Zeitfenster: from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation or discharge
|
from inclusion at postmenstrual age <30 weeks until 36 weeks of gestation or discharge
|
|
|
Oxidative stress by 8-Oxo-2'-deoxyguanosine metabolites in urine
Zeitfenster: from inclusion at postmenstrual age <30 weeks until discharge
|
Measured by mass spectroscopy
|
from inclusion at postmenstrual age <30 weeks until discharge
|
|
Protein synthesis analyzed by nitrogen excretion in urine [µmol/mL]
Zeitfenster: first three weeks during intervention before 36 weeks of gestation
|
first three weeks during intervention before 36 weeks of gestation
|
|
|
Feeding intolerance questionaire
Zeitfenster: from inclusion at postmenstrual age <30 weeks until discharge
|
volume of gastric residuals, color of gastric residuals, vomiting, abdominal girth, abdominal distention
|
from inclusion at postmenstrual age <30 weeks until discharge
|
|
Fat mass [g]
Zeitfenster: from inclusion at postmenstrual age <30 weeks until discharge
|
Measured with bioelectrical impedance analysis
|
from inclusion at postmenstrual age <30 weeks until discharge
|
|
Lean mass [g]
Zeitfenster: from inclusion at postmenstrual age <30 weeks until discharge
|
Measured with bioelectrical impedance analysis
|
from inclusion at postmenstrual age <30 weeks until discharge
|
|
Head circumference [cm]
Zeitfenster: from inclusion at postmenstrual age <30 weeks until discharge
|
Measured by tape
|
from inclusion at postmenstrual age <30 weeks until discharge
|
|
Body length [cm]
Zeitfenster: from inclusion at postmenstrual age <30 weeks until discharge
|
Measured by length board
|
from inclusion at postmenstrual age <30 weeks until discharge
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Christoph Fusch, MD, PhD, McMaster Children's Hospital
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Fusch G, Rochow N, Choi A, Fusch S, Poeschl S, Ubah AO, Lee SY, Raja P, Fusch C. Rapid measurement of macronutrients in breast milk: How reliable are infrared milk analyzers? Clin Nutr. 2015 Jun;34(3):465-76. doi: 10.1016/j.clnu.2014.05.005. Epub 2014 May 17.
- Rochow N, Fusch G, Choi A, Chessell L, Elliott L, McDonald K, Kuiper E, Purcha M, Turner S, Chan E, Xia MY, Fusch C. Target fortification of breast milk with fat, protein, and carbohydrates for preterm infants. J Pediatr. 2013 Oct;163(4):1001-7. doi: 10.1016/j.jpeds.2013.04.052. Epub 2013 Jun 12.
- Choi A, Fusch G, Rochow N, Sheikh N, Fusch C. Establishment of micromethods for macronutrient contents analysis in breast milk. Matern Child Nutr. 2015 Oct;11(4):761-72. doi: 10.1111/mcn.12053. Epub 2013 Jun 18.
- Fusch G, Choi A, Rochow N, Fusch C. Quantification of lactose content in human and cow's milk using UPLC-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Dec 1;879(31):3759-62. doi: 10.1016/j.jchromb.2011.09.053. Epub 2011 Oct 6.
- Fusch G, Mitra S, Rochow N, Fusch C. Target fortification of breast milk: levels of fat, protein or lactose are not related. Acta Paediatr. 2015 Jan;104(1):38-42. doi: 10.1111/apa.12804. Epub 2014 Oct 2.
- Rochow N, Landau-Crangle E, Fusch C. Challenges in breast milk fortification for preterm infants. Curr Opin Clin Nutr Metab Care. 2015 May;18(3):276-84. doi: 10.1097/MCO.0000000000000167.
- Rochow N, Fusch G, Zapanta B, Ali A, Barui S, Fusch C. Target fortification of breast milk: how often should milk analysis be done? Nutrients. 2015 Apr 1;7(4):2297-310. doi: 10.3390/nu7042297.
- Fusch G, Kwan C, Huang RC, Rochow N, Fusch C. Need of quality control programme when using near-infrared human milk analyzers. Acta Paediatr. 2016 Mar;105(3):324-5. doi: 10.1111/apa.13305. Epub 2016 Jan 19. No abstract available.
- Choi A, Fusch G, Rochow N, Fusch C. Target Fortification of Breast Milk: Predicting the Final Osmolality of the Feeds. PLoS One. 2016 Feb 10;11(2):e0148941. doi: 10.1371/journal.pone.0148941. eCollection 2016.
- Kotrri G, Fusch G, Kwan C, Choi D, Choi A, Al Kafi N, Rochow N, Fusch C. Validation of Correction Algorithms for Near-IR Analysis of Human Milk in an Independent Sample Set-Effect of Pasteurization. Nutrients. 2016 Feb 26;8(3):119. doi: 10.3390/nu8030119.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2016TFO2
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Postnatale Wachstumsstörung
-
Duke UniversityAktiv, nicht rekrutierend
-
Johns Hopkins Bloomberg School of Public HealthmPower Social Enterprises Limited; The JiVitA ProjectAbgeschlossenHohe perinatale Mortalität | Hohe Neugeborenensterblichkeit | Geringe Inanspruchnahme von Schwangerschaftsvorsorgediensten | Geringe Inanspruchnahme von Postnatal Care-DienstenBangladesch
-
Taipei Veterans General Hospital, TaiwanNational Yang Ming UniversityUnbekanntEpithelial Growth Factor Receptor Negativer nicht-kleinzelliger Lungenkrebs
-
Shanghai Junshi Bioscience Co., Ltd.Noch keine RekrutierungLokal fortgeschrittenes, metastasiertes oder rezidivierendes nicht-kleinzelliges Lungenkarzinom (NSCLC) mit Epidermal-Growth-Factor-Rezeptor (EGFR)-MutationenChina
Klinische Studien zur Fortification with modular protein
-
University of NebraskaAlegent Health Bergan Mercy Medical CenterAbgeschlossenProblem mit dem Wachstum eines SäuglingsVereinigte Staaten